CGON

CG Oncology (CGON)

About CG Oncology (CGON)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Details

Daily high

$39.83

Daily low

$37.73

Price at open

$38.04

52 Week High

$46.01

52 Week Low

$14.80

Market cap

3.1B

Dividend yield

0.00%

Volume

3.2M

Avg. volume

899,231

P/E ratio

-19.67

CG Oncology News